IN THE CLAIMS

1-42. (canceled)

43. (currently amended) A nucleic acid molecule selected from a group consisting of

i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2,

ii) nucleic acid molecules comprising the sequence of SEQ ID NO:1, and

iii) nucleic acid molecules consisting of the sequence of SEQ ID NO:1~~,~~

~~iv) nucleic acid molecules the complementary strand of which hybridizes under stringent conditions to a nucleic acid molecule of (i), (ii), or (iii); and~~

~~v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid molecule of (iii) due to the degeneracy of the genetic code~~;

~~wherein the polypeptide encoded by the nucleic acid molecule has MGAT-X1 activity~~.

44. (canceled)

45. (previously presented) A vector comprising the nucleic acid molecule of claim 43.

46. (currently amended) [[A]] An isolated host cell containing a vector comprising the nucleic acid molecule of claim 43.

47. (currently amended) A method of producing a polypeptide ~~MGAT-X1~~, comprising:

i) culturing a host cell comprising a vector which comprises the nucleic acid molecule of claim 46 under ~~suitable~~ conditions suitable for the polypeptide to be expressed; and

ii) recovering the polypeptide ~~MGAT-X1~~ from the culture medium.

48-71. (canceled)

72. (currently amended) A pharmaceutical composition comprising a nucleic acid molecule selected from the group consisting of:

i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2,

ii) nucleic acid molecules comprising the sequence of SEQ ID NO:1, and

~~iii) nucleic acid molecules having the sequence of SEQ ID NO:1,~~

~~iv) nucleic acid molecules the complementary strand of which hybridizes under stringent conditions to a nucleic acid molecule of (i), (ii), or (iii); and~~

~~v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid molecule of (iii) due to the degeneracy of the genetic code;~~

~~wherein the polypeptide encoded by the nucleic acid molecule has MGAT-X1 activity~~.

73. (currently amended) A pharmaceutical composition comprising a vector comprising a nucleic acid molecule selected from a group consisting of

i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2,

ii) nucleic acid molecules comprising the sequence of SEQ ID NO:1, and

iii) nucleic acid molecules having the sequence of SEQ ID NO:1~~,~~

~~iv) nucleic acid molecules the complementary strand of which hybridizes under stringent conditions to a nucleic acid molecule of (i), (ii), or (iii); and~~

~~v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid molecule of (iii) due to the degeneracy of the genetic code~~;

~~wherein the polypeptide encoded by the nucleic acid molecule has MGAT-X1 activity~~.

74-75. (canceled)